Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2015-12

AUTHORS

Ahmet Gül, Huri Ozdogan, Burak Erer, Serdal Ugurlu, Ozgur Kasapcopur, Nicole Davis, Serhan Sevgi

ABSTRACT

INTRODUCTION: This open-label pilot study aimed to investigate the efficacy of canakinumab in colchicine-resistant familial Mediterranean fever (FMF) patients. METHOD: Patients with one or more attacks in a month in the preceding 3 months despite colchicine were eligible to enter a 30-day run-in period. Patients who had an attack during the first run-in period advanced to a second 30-day period. At the first attack, patients started to receive three canakinumab 150 mg subcutaneous injections at 4-week intervals, and were then followed for an additional 2 months. Primary efficacy outcome measure was the proportion of patients with 50 % or more reduction in attack frequency. Secondary outcome measures included time to next attack following last canakinumab dose and changes in quality of life assessed by SF-36. RESULTS: Thirteen patients were enrolled in the run-in period and 9 advanced to the treatment period. All 9 patients achieved a 50 % or more reduction in attack frequency, and only one patient had an attack during the treatment period. C-reactive protein and serum amyloid A protein levels remained low throughout the treatment period. Significant improvement was observed in both physical and mental component scores of the Short Form-36 at Day 8. Five patients had an attack during the 2-month follow-up, occurring median 71 (range, 31 to 78) days after the last dose. Adverse events were similar to those observed in the previous canakinumab trials. CONCLUSION: Canakinumab was effective at controlling the attack recurrence in patients with FMF resistant to colchicine. Further investigations are warranted to explore canakinumab's potential in the treatment of patients with colchicine resistant FMF. TRIAL REGISTRATION: ClinicalTrials.gov NCT01088880 . Registered 16 March 2010. More... »

PAGES

243

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s13075-015-0765-4

DOI

http://dx.doi.org/10.1186/s13075-015-0765-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1012123238

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/26337145


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "C-Reactive Protein", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Child", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Colchicine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Resistance", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Familial Mediterranean Fever", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Headache", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pilot Projects", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Surveys and Questionnaires", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tubulin Modulators", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vomiting", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Istanbul University", 
          "id": "https://www.grid.ac/institutes/grid.9601.e", 
          "name": [
            "Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, 34093 Fatih, Istanbul, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "G\u00fcl", 
        "givenName": "Ahmet", 
        "id": "sg:person.0603062573.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603062573.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Cerrahpasa Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ozdogan", 
        "givenName": "Huri", 
        "id": "sg:person.01202325160.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01202325160.70"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Istanbul University", 
          "id": "https://www.grid.ac/institutes/grid.9601.e", 
          "name": [
            "Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, 34093 Fatih, Istanbul, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Erer", 
        "givenName": "Burak", 
        "id": "sg:person.01157712005.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01157712005.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Cerrahpasa Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ugurlu", 
        "givenName": "Serdal", 
        "id": "sg:person.01200675141.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01200675141.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Istanbul University", 
          "id": "https://www.grid.ac/institutes/grid.9601.e", 
          "name": [
            "Department of Pediatrics, Istanbul University, Istanbul, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kasapcopur", 
        "givenName": "Ozgur", 
        "id": "sg:person.01067045144.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01067045144.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418424.f", 
          "name": [
            "Novartis Pharmaceutical Corporation, East Hanover, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Davis", 
        "givenName": "Nicole", 
        "id": "sg:person.01011540753.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01011540753.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Novartis Pharmaceutical Corporation, Istanbul, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sevgi", 
        "givenName": "Serhan", 
        "id": "sg:person.01156460000.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01156460000.35"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s12016-013-8358-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004941408", 
          "https://doi.org/10.1007/s12016-013-8358-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(97)09408-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016372510"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1205099", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016774916"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0049-0172(91)90019-v", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019134656"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0049-0172(91)90019-v", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019134656"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm197410312911803", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019861744"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/ar3535", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020070762", 
          "https://doi.org/10.1186/ar3535"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa0810787", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026897774"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm197410312911804", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035986098"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1146/annurev.immunol.25.022106.141627", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039143240"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/art.1780401023", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039294755"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.autrev.2012.07.025", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040647917"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.semarthrit.2010.11.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045746217"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm198604173141601", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052921204"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.7326/0003-4819-157-8-201210160-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1073713212"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2015-12", 
    "datePublishedReg": "2015-12-01", 
    "description": "INTRODUCTION: This open-label pilot study aimed to investigate the efficacy of canakinumab in colchicine-resistant familial Mediterranean fever (FMF) patients.\nMETHOD: Patients with one or more attacks in a month in the preceding 3 months despite colchicine were eligible to enter a 30-day run-in period. Patients who had an attack during the first run-in period advanced to a second 30-day period. At the first attack, patients started to receive three canakinumab 150 mg subcutaneous injections at 4-week intervals, and were then followed for an additional 2 months. Primary efficacy outcome measure was the proportion of patients with 50 % or more reduction in attack frequency. Secondary outcome measures included time to next attack following last canakinumab dose and changes in quality of life assessed by SF-36.\nRESULTS: Thirteen patients were enrolled in the run-in period and 9 advanced to the treatment period. All 9 patients achieved a 50 % or more reduction in attack frequency, and only one patient had an attack during the treatment period. C-reactive protein and serum amyloid A protein levels remained low throughout the treatment period. Significant improvement was observed in both physical and mental component scores of the Short Form-36 at Day 8. Five patients had an attack during the 2-month follow-up, occurring median 71 (range, 31 to 78) days after the last dose. Adverse events were similar to those observed in the previous canakinumab trials.\nCONCLUSION: Canakinumab was effective at controlling the attack recurrence in patients with FMF resistant to colchicine. Further investigations are warranted to explore canakinumab's potential in the treatment of patients with colchicine resistant FMF.\nTRIAL REGISTRATION: ClinicalTrials.gov NCT01088880 . Registered 16 March 2010.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s13075-015-0765-4", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1297499", 
        "issn": [
          "1478-6354", 
          "1478-6362"
        ], 
        "name": "Arthritis Research & Therapy", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "17"
      }
    ], 
    "name": "Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever", 
    "pagination": "243", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "39c23c4375d7ad5cf6e9dd483aacf5c5ee9dd26158f36d07a54851ea0e017cc9"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "26337145"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101154438"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s13075-015-0765-4"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1012123238"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s13075-015-0765-4", 
      "https://app.dimensions.ai/details/publication/pub.1012123238"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T19:57", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8681_00000511.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1186%2Fs13075-015-0765-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13075-015-0765-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13075-015-0765-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13075-015-0765-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13075-015-0765-4'


 

This table displays all metadata directly associated to this object as RDF triples.

241 TRIPLES      21 PREDICATES      62 URIs      40 LITERALS      28 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s13075-015-0765-4 schema:about N0310c7ac03254555b0f1e30660bdd5b8
2 N04995bc20b7d4adf913ef8597069ba8e
3 N089f73f9351441f78ee53ab8485c6cf3
4 N0cca7f822cdf4267b5ff723a47b4cb8f
5 N133249ce2b4247e9a6d6921736fbd980
6 N2ed926a621bf43cb8e5412848142472e
7 N458e6e6155bc4573be7f505f797145f1
8 N56fb0b89671449a899f5bbb0a2da0b10
9 N889e87d5f0774909890c4a0dbdbdc3aa
10 N88f896e624bc414c9f39e3100f1f93df
11 N95cfa56836224d589cdb4f151559a371
12 N974b65c27d20471399307582ea1219e3
13 N9f83ab4dc7d3472f978ef96b15ee80c6
14 Nc549c3e9908b4c7ab34d7e43bbbdcdc3
15 Nc76afd0d1ac64f61859e842cabc5e344
16 Nd3f49468a68046caa993df627ad09efd
17 Ne15c0f3fa377452da78ee2b48ed81a32
18 Ne431c189895b444aa3b3d95bbf20962d
19 Nf8da90cd52a9499ea1581b443d3fa0ae
20 anzsrc-for:11
21 anzsrc-for:1103
22 schema:author N0b9e7982fc5f4c37b4f580bad85c6968
23 schema:citation sg:pub.10.1007/s12016-013-8358-y
24 sg:pub.10.1186/ar3535
25 https://doi.org/10.1002/art.1780401023
26 https://doi.org/10.1016/0049-0172(91)90019-v
27 https://doi.org/10.1016/j.autrev.2012.07.025
28 https://doi.org/10.1016/j.semarthrit.2010.11.003
29 https://doi.org/10.1016/s0140-6736(97)09408-7
30 https://doi.org/10.1056/nejm197410312911803
31 https://doi.org/10.1056/nejm197410312911804
32 https://doi.org/10.1056/nejm198604173141601
33 https://doi.org/10.1056/nejmoa0810787
34 https://doi.org/10.1056/nejmoa1205099
35 https://doi.org/10.1146/annurev.immunol.25.022106.141627
36 https://doi.org/10.7326/0003-4819-157-8-201210160-00003
37 schema:datePublished 2015-12
38 schema:datePublishedReg 2015-12-01
39 schema:description INTRODUCTION: This open-label pilot study aimed to investigate the efficacy of canakinumab in colchicine-resistant familial Mediterranean fever (FMF) patients. METHOD: Patients with one or more attacks in a month in the preceding 3 months despite colchicine were eligible to enter a 30-day run-in period. Patients who had an attack during the first run-in period advanced to a second 30-day period. At the first attack, patients started to receive three canakinumab 150 mg subcutaneous injections at 4-week intervals, and were then followed for an additional 2 months. Primary efficacy outcome measure was the proportion of patients with 50 % or more reduction in attack frequency. Secondary outcome measures included time to next attack following last canakinumab dose and changes in quality of life assessed by SF-36. RESULTS: Thirteen patients were enrolled in the run-in period and 9 advanced to the treatment period. All 9 patients achieved a 50 % or more reduction in attack frequency, and only one patient had an attack during the treatment period. C-reactive protein and serum amyloid A protein levels remained low throughout the treatment period. Significant improvement was observed in both physical and mental component scores of the Short Form-36 at Day 8. Five patients had an attack during the 2-month follow-up, occurring median 71 (range, 31 to 78) days after the last dose. Adverse events were similar to those observed in the previous canakinumab trials. CONCLUSION: Canakinumab was effective at controlling the attack recurrence in patients with FMF resistant to colchicine. Further investigations are warranted to explore canakinumab's potential in the treatment of patients with colchicine resistant FMF. TRIAL REGISTRATION: ClinicalTrials.gov NCT01088880 . Registered 16 March 2010.
40 schema:genre research_article
41 schema:inLanguage en
42 schema:isAccessibleForFree true
43 schema:isPartOf N0e93f41d92ba49a9acad890c4ef8937a
44 N573503f256f24750861dff0e40fbff14
45 sg:journal.1297499
46 schema:name Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever
47 schema:pagination 243
48 schema:productId N5ef6d9074a5f42539a17eaee56670ac9
49 N899de473c33040019221be7b682348e9
50 Nb079c485230a4cdd8143e6a6eee6beee
51 Nd9254338cb7547c9815b57ee56634c28
52 Ne36309450bf949fe8a3abd781c68ce49
53 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012123238
54 https://doi.org/10.1186/s13075-015-0765-4
55 schema:sdDatePublished 2019-04-10T19:57
56 schema:sdLicense https://scigraph.springernature.com/explorer/license/
57 schema:sdPublisher N9f7c6e2d398640f2b97c3849fa8b600d
58 schema:url http://link.springer.com/10.1186%2Fs13075-015-0765-4
59 sgo:license sg:explorer/license/
60 sgo:sdDataset articles
61 rdf:type schema:ScholarlyArticle
62 N0310c7ac03254555b0f1e30660bdd5b8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
63 schema:name Child
64 rdf:type schema:DefinedTerm
65 N04995bc20b7d4adf913ef8597069ba8e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
66 schema:name Surveys and Questionnaires
67 rdf:type schema:DefinedTerm
68 N089f73f9351441f78ee53ab8485c6cf3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
69 schema:name Young Adult
70 rdf:type schema:DefinedTerm
71 N0b9e7982fc5f4c37b4f580bad85c6968 rdf:first sg:person.0603062573.29
72 rdf:rest Nf2505314ed384a9e89500ac8c4dded57
73 N0cca7f822cdf4267b5ff723a47b4cb8f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
74 schema:name Adult
75 rdf:type schema:DefinedTerm
76 N0e93f41d92ba49a9acad890c4ef8937a schema:issueNumber 1
77 rdf:type schema:PublicationIssue
78 N133249ce2b4247e9a6d6921736fbd980 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
79 schema:name Antibodies, Monoclonal
80 rdf:type schema:DefinedTerm
81 N2ed926a621bf43cb8e5412848142472e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
82 schema:name Humans
83 rdf:type schema:DefinedTerm
84 N458e6e6155bc4573be7f505f797145f1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Colchicine
86 rdf:type schema:DefinedTerm
87 N45e8a57730384e3bb15670bc3f52f64b rdf:first sg:person.01200675141.44
88 rdf:rest Ndd0336d0373941b68ba3e3ed11ea07a9
89 N56fb0b89671449a899f5bbb0a2da0b10 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Drug Resistance
91 rdf:type schema:DefinedTerm
92 N573503f256f24750861dff0e40fbff14 schema:volumeNumber 17
93 rdf:type schema:PublicationVolume
94 N599cc809e4394b7b8730b0f085869ace rdf:first sg:person.01156460000.35
95 rdf:rest rdf:nil
96 N5ef6d9074a5f42539a17eaee56670ac9 schema:name nlm_unique_id
97 schema:value 101154438
98 rdf:type schema:PropertyValue
99 N889e87d5f0774909890c4a0dbdbdc3aa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Treatment Outcome
101 rdf:type schema:DefinedTerm
102 N88f896e624bc414c9f39e3100f1f93df schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Familial Mediterranean Fever
104 rdf:type schema:DefinedTerm
105 N899de473c33040019221be7b682348e9 schema:name dimensions_id
106 schema:value pub.1012123238
107 rdf:type schema:PropertyValue
108 N8ca33d128a7a42229072f512a6ca4d0f schema:name Cerrahpasa Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
109 rdf:type schema:Organization
110 N95cfa56836224d589cdb4f151559a371 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Male
112 rdf:type schema:DefinedTerm
113 N974b65c27d20471399307582ea1219e3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name C-Reactive Protein
115 rdf:type schema:DefinedTerm
116 N9f7c6e2d398640f2b97c3849fa8b600d schema:name Springer Nature - SN SciGraph project
117 rdf:type schema:Organization
118 N9f83ab4dc7d3472f978ef96b15ee80c6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Tubulin Modulators
120 rdf:type schema:DefinedTerm
121 Nb079c485230a4cdd8143e6a6eee6beee schema:name readcube_id
122 schema:value 39c23c4375d7ad5cf6e9dd483aacf5c5ee9dd26158f36d07a54851ea0e017cc9
123 rdf:type schema:PropertyValue
124 Nbeebd73dfa224982924fb0c74ba347ff schema:name Cerrahpasa Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
125 rdf:type schema:Organization
126 Nc549c3e9908b4c7ab34d7e43bbbdcdc3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Headache
128 rdf:type schema:DefinedTerm
129 Nc76afd0d1ac64f61859e842cabc5e344 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Pilot Projects
131 rdf:type schema:DefinedTerm
132 Nc9baa5c23cb242c184c31a59c7beb682 rdf:first sg:person.01011540753.45
133 rdf:rest N599cc809e4394b7b8730b0f085869ace
134 Nd3f49468a68046caa993df627ad09efd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Drug Administration Schedule
136 rdf:type schema:DefinedTerm
137 Nd9254338cb7547c9815b57ee56634c28 schema:name doi
138 schema:value 10.1186/s13075-015-0765-4
139 rdf:type schema:PropertyValue
140 Ndd0336d0373941b68ba3e3ed11ea07a9 rdf:first sg:person.01067045144.42
141 rdf:rest Nc9baa5c23cb242c184c31a59c7beb682
142 Ne15c0f3fa377452da78ee2b48ed81a32 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Vomiting
144 rdf:type schema:DefinedTerm
145 Ne36309450bf949fe8a3abd781c68ce49 schema:name pubmed_id
146 schema:value 26337145
147 rdf:type schema:PropertyValue
148 Ne431c189895b444aa3b3d95bbf20962d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Female
150 rdf:type schema:DefinedTerm
151 Neb16fd0a59d14d449fc89c97b157c43a schema:name Novartis Pharmaceutical Corporation, Istanbul, Turkey
152 rdf:type schema:Organization
153 Nf2505314ed384a9e89500ac8c4dded57 rdf:first sg:person.01202325160.70
154 rdf:rest Nf691c291d6c4409bbcd2ad7e7fdaf633
155 Nf691c291d6c4409bbcd2ad7e7fdaf633 rdf:first sg:person.01157712005.10
156 rdf:rest N45e8a57730384e3bb15670bc3f52f64b
157 Nf8da90cd52a9499ea1581b443d3fa0ae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Adolescent
159 rdf:type schema:DefinedTerm
160 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
161 schema:name Medical and Health Sciences
162 rdf:type schema:DefinedTerm
163 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
164 schema:name Clinical Sciences
165 rdf:type schema:DefinedTerm
166 sg:journal.1297499 schema:issn 1478-6354
167 1478-6362
168 schema:name Arthritis Research & Therapy
169 rdf:type schema:Periodical
170 sg:person.01011540753.45 schema:affiliation https://www.grid.ac/institutes/grid.418424.f
171 schema:familyName Davis
172 schema:givenName Nicole
173 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01011540753.45
174 rdf:type schema:Person
175 sg:person.01067045144.42 schema:affiliation https://www.grid.ac/institutes/grid.9601.e
176 schema:familyName Kasapcopur
177 schema:givenName Ozgur
178 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01067045144.42
179 rdf:type schema:Person
180 sg:person.01156460000.35 schema:affiliation Neb16fd0a59d14d449fc89c97b157c43a
181 schema:familyName Sevgi
182 schema:givenName Serhan
183 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01156460000.35
184 rdf:type schema:Person
185 sg:person.01157712005.10 schema:affiliation https://www.grid.ac/institutes/grid.9601.e
186 schema:familyName Erer
187 schema:givenName Burak
188 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01157712005.10
189 rdf:type schema:Person
190 sg:person.01200675141.44 schema:affiliation Nbeebd73dfa224982924fb0c74ba347ff
191 schema:familyName Ugurlu
192 schema:givenName Serdal
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01200675141.44
194 rdf:type schema:Person
195 sg:person.01202325160.70 schema:affiliation N8ca33d128a7a42229072f512a6ca4d0f
196 schema:familyName Ozdogan
197 schema:givenName Huri
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01202325160.70
199 rdf:type schema:Person
200 sg:person.0603062573.29 schema:affiliation https://www.grid.ac/institutes/grid.9601.e
201 schema:familyName Gül
202 schema:givenName Ahmet
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603062573.29
204 rdf:type schema:Person
205 sg:pub.10.1007/s12016-013-8358-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1004941408
206 https://doi.org/10.1007/s12016-013-8358-y
207 rdf:type schema:CreativeWork
208 sg:pub.10.1186/ar3535 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020070762
209 https://doi.org/10.1186/ar3535
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1002/art.1780401023 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039294755
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1016/0049-0172(91)90019-v schema:sameAs https://app.dimensions.ai/details/publication/pub.1019134656
214 rdf:type schema:CreativeWork
215 https://doi.org/10.1016/j.autrev.2012.07.025 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040647917
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1016/j.semarthrit.2010.11.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045746217
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1016/s0140-6736(97)09408-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016372510
220 rdf:type schema:CreativeWork
221 https://doi.org/10.1056/nejm197410312911803 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019861744
222 rdf:type schema:CreativeWork
223 https://doi.org/10.1056/nejm197410312911804 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035986098
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1056/nejm198604173141601 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052921204
226 rdf:type schema:CreativeWork
227 https://doi.org/10.1056/nejmoa0810787 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026897774
228 rdf:type schema:CreativeWork
229 https://doi.org/10.1056/nejmoa1205099 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016774916
230 rdf:type schema:CreativeWork
231 https://doi.org/10.1146/annurev.immunol.25.022106.141627 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039143240
232 rdf:type schema:CreativeWork
233 https://doi.org/10.7326/0003-4819-157-8-201210160-00003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1073713212
234 rdf:type schema:CreativeWork
235 https://www.grid.ac/institutes/grid.418424.f schema:alternateName Novartis (United States)
236 schema:name Novartis Pharmaceutical Corporation, East Hanover, NJ, USA
237 rdf:type schema:Organization
238 https://www.grid.ac/institutes/grid.9601.e schema:alternateName Istanbul University
239 schema:name Department of Pediatrics, Istanbul University, Istanbul, Turkey
240 Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, 34093 Fatih, Istanbul, Turkey
241 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...